Recently, the innovative molecular diagnostics company Biocartis announced that it is launching a multiple diagnostic test, the Idylla SARS-CoV-2/Flu/RSV Panel. Within 90 minutes, this test can identify if a patient is suffering from COVID-19, flu, or another respiratory virus. The test has already been approved in Europe and countries that recognize the European CE mark. An application for authorization has yet to be submitted to the FDA (Food and Drug Administration) of the United States.
You are here
New test for COVID-19, flu and SARS developed in Flanders
In anticipation of a delayed flu season, this test can guide healthcare providers through a complex landscape of respiratory infections in 2022.
Biocartis reports it can look back on a strong first half of the year. Both the number of Idylla molecular testing systems and corresponding cartridges sold were above expectations. The company also saw great success with its oncology tests, as well as with their tests for infectious diseases.